PlaqueTec

PlaqueTec is pioneering the development of biomarker-based strategies to transform the prevention, diagnosis, and treatment of Coronary Artery Disease, the leading cause of death worldwide.

As with any successful startup, PlaqueTec has a strong leadership team with a unified vision for continued growth, and a commitment to changing the current standard of care in the diagnosis, prevention, and treatment of CAD. They work closely with cardiologists, academic scientists, and biopharmaceutical companies around the world to advance understanding of CAD and the inflammatory processes underlying the progression of this common and dangerous disease, and to accelerate the testing of existing and new therapeutic agents for CAD.

PlaqueTec headquartered in Europe, operates in the Health Care sector. The company focuses on Health Care and has secured $32.0M in funding across 4 round(s). With a team of 1-10 employees, PlaqueTec is actively contributing to advancements in Health Care. Their latest funding round, Venture Round - PlaqueTec, raised $8.0M. Discover more about their projects, partnerships, and impact on our platform.